← peptides typeshit

O'Shea Hogan Labs flags dropout concerns in retatrutide's phase 3 data

The account calls the up to 28% weight loss impressive but says only about half of participants finished, citing nausea, constipation and skin sensitivity.

See it on Instagram

Recap by typeshit. Post by @osheahoganlabs on Instagram.